Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells $1,773,474.22 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 29,494 shares of Liquidia stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $60.13, for a total transaction of $1,773,474.22. Following the completion of the sale, the director directly owned 38,755 shares of the company’s stock, valued at approximately $2,330,338.15. This trade represents a 43.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Liquidia Stock Performance

LQDA opened at $62.03 on Friday. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $63.46. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The company has a market cap of $5.52 billion, a P/E ratio of 443.10 and a beta of 0.41. The company has a fifty day moving average price of $44.03 and a two-hundred day moving average price of $38.31.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. The firm’s revenue for the quarter was up 4187.1% on a year-over-year basis. Analysts predict that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on LQDA shares. HC Wainwright lifted their price target on shares of Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Wells Fargo & Company lifted their price target on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Finally, Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.88.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. Federated Hermes Inc. purchased a new position in Liquidia in the third quarter valued at approximately $7,290,000. Caprock Group LLC purchased a new stake in shares of Liquidia during the 3rd quarter valued at approximately $37,114,000. Apis Capital Advisors LLC purchased a new stake in shares of Liquidia during the 3rd quarter valued at approximately $9,569,000. Farallon Capital Management LLC lifted its stake in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its stake in shares of Liquidia by 63.6% during the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after buying an additional 24,555 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).